While specific Defitelio coupons or discount programs are not publicly detailed in the provided information, pharmaceutical manufacturers often offer patient assistance programs for their medications [1]. These programs can help reduce out-of-pocket costs for eligible patients who have commercial insurance and face high co-pays, or for those who are uninsured [1].
What assistance is available for Defitelio costs?
Patients seeking financial assistance for Defitelio should explore manufacturer-sponsored programs. These typically involve an application process and have eligibility requirements based on insurance status and income [1]. It is advisable for patients to inquire directly with the Defitelio manufacturer or their healthcare provider about available support options [1].
How does Defitelio work?
Defitelio (defibrotide sodium) is a novel hemostatic agent used for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in pediatric and adult patients undergoing hematopoietic stem cell transplantation (HSCT) [2]. It works by normalizing the fibrinolytic system, which is dysregulated in VOD/SOS [2]. Defibrotide is a deoxyribonucleic acid derivative that exhibits antithrombotic and profibrinolytic properties [2]. It is believed to restore the balance between procoagulant and anticoagulant factors, thereby reducing clot formation and promoting clot breakdown [2].
What are the side effects of Defitelio?
Common side effects associated with Defitelio include diarrhea, nausea, vomiting, and hypotension [3]. More serious side effects can involve hypersensitivity reactions and bleeding events [3]. It is crucial for patients to report any adverse reactions to their healthcare provider immediately [3].
What is the recommended dosage for Defitelio?
The recommended dose of Defitelio is 6.25 mg/kg every 6 hours [3]. It is administered intravenously over approximately 30 minutes [3]. The duration of treatment is typically up to 21 days, or until recovery from VOD/SOS [3].
What is Hepatic Veno-Occlusive Disease (VOD)?
Hepatic Veno-Occlusive Disease (VOD), also referred to as sinusoidal obstruction syndrome (SOS), is a serious complication that can occur after myeloablative therapy, often in the context of hematopoietic stem cell transplantation (HSCT) [2]. It is characterized by the obstruction of the hepatic sinusoids and small hepatic veins, leading to liver dysfunction, fluid accumulation in the abdomen, and other organ damage [2]. The pathophysiology involves endothelial damage and subsequent activation of coagulation and fibrinolysis within the liver [2].
What is the regulatory status of Defitelio?
Defitelio received approval from the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of severe VOD/SOS in pediatric and adult patients [2]. It is also approved in the European Union and other countries [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/defitelio/patient-assistance
[2] https://www.rxlist.com/defitelio-drug-market-status.htm
[3] https://www.rxlist.com/defitelio-side-effects-drug-center.htm